Alzinova AB (publ) (STO:ALZ)

Market Cap	171.93M
Revenue (ttm)	20.05M
Net Income (ttm)	-21.27M
Shares Out	104.32M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	54.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,400
Average Volume	902,110
Open	1.648
Previous Close	1.648
Day's Range	1.648 - 1.648
52-Week Range	1.500 - 4.620
Beta	1.16
RSI	47.20
Earnings Date	Aug 21, 2025

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.